Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

Starting soon

Conditions studied: Non-Small Cell Lung Cancer

In brief

This observational study evaluates the real-world safety and effectiveness of repotrectinib in Korean participants with locally advanced or metastatic ROS1-positive non-small cell lung cancer or solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Participants receiving repotrectinib in routine clinical practice will be followed for up to 12 months or until the end of the 2-year surveillance period, whichever occurs first.

Key facts

Study ID

NCT07599007

Run by

Bristol-Myers Squibb

People needed

10

Starts

2026-05-24

Expected to finish

2028-01-31

Last updated by the study team

2026-05-20

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants aged ≥19 years with histologically OR cytologically confirmed locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)
• Participants aged ≥12 years with solid tumors harboring Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions
• Documented ROS1 or NTRK 1-3 gene fusion by validated local testing
• Written informed consent

You may not qualify if…

• Treatment with repotrectinib for indications not approved in Korea
• Treatment with repotrectinib at dosages not approved in Korea
• Contraindication to repotrectinib according to MFDS prescribing information

Where it is running

• Bristol Myers Squibb Pharmaceutical Korea Ltd — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.